Interim

Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

Amy J. Foley October 6, 2022 0

&#13 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Stage 1 demo of ETX-155 for major depressive condition (MDD) and epilepsy. &#13...

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

The Evolution of Russian Royal Engagement Rings and Their Mystique

4 Tips to Boost Your Home’s Value Through Remodeling

The rise of the internet

Qualities to Look for When Purchasing Hospitality Work Uniforms

Sustainable Practices in Green Manufacturing for a Greener Future

Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

Related Article

The Evolution of Russian Royal Engagement Rings and Their Mystique

4 Tips to Boost Your Home’s Value Through Remodeling

The rise of the internet

Qualities to Look for When Purchasing Hospitality Work Uniforms

Sustainable Practices in Green Manufacturing for a Greener Future